| CV risicomanagement: First things first |
| | CV risicomanagement : First things First |
|
| 70th Scientific Sessions ADA |
| | DM 2, HbA1c, en CHZ |
|
| Haffner, NEJM,1998 |
| | DCCTmean HbA1c in type 1 diabetes |
|
| EDIC studyfollow-up 8 years after DCCT |
| | DCCT / EDIC studycardiovascular disease |
|
| UKPDS : relatie HbA1c en complicaties |
| | Post-Trial Changes in HbA1c |
|
| Myocardial Infarction Hazard Ratio |
| | Myocardial Infarction Hazard Ratio |
|
| ADVANCE : HbA1c : 6,4 vs 7,0 % |
| | ACCORD : HbA1c : 6,4 vs 7,5 % |
|
| Scherpe regulatie bij dm2 : |
| | Post-Trials Changes in Blood Pressure |
|
| Myocardial Infarction Hazard Ratios |
| | BP : hoe laag ? :ACCORD-BP studie |
|
| BP : hoe laag ? :ACCORD-BP studie |
| | Lipiden-verlaging bij dm2 : statines |
|
| Lipiden-verlaging bij dm2: fibraten |
| | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD(Detection of silent Ischemia in Asymptomatic Diabetic subjects) |
|
| Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD(Detection of silent Ischemia in Asymptomatic Diabetic subjects) |
| | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD |
|
| Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD:1-3 |
| | Cardiovasulaire Incidenten en glucose-verlagende medicatie : effect van metformin : de REACH-studie |
|
| REACH-registry |
| | REACH-registry |
|
| REACH-registry |
| | REACH-registry |
|
| REACH-registry |
| | Cardiovasulaire Incidenten en glucose-verlagende medicatie “ The Rosiglitazone-story ” |
|
| “ the rosiglitazone-story “ |
| | “ the rosiglitazone-story “ |
|
| “ the rosiglitazone-story “ |
| | “ the rosiglitazone-story “ |
|
| Cardiovasculaire effecten van glucoseverlagende medicatie : GLP-1-analogen |
| | Slide 38 |
|
| Slide 39 |
| | Subgroep : TG > 2,3 en HDL-c < 0,9 |
|
| Subgroep : TG > 2,3 en HDL-c < 0,9 |
| | Voor de praktijk :Diabetes 2 en Cardiovasculaire complicaties |
|
| Voor de praktijk :Diabetes 2 en Cardiovasculaire complicaties |
|
Deel deze pagina met collega's en vrienden: